ARA-290 (Cibinetide)
Cibinetide; ARA290; Helix B Surface Peptide (HBSP); pyroglutamate helix-B surface peptide (pHBSP)
The Ground Truth Score
four plain questions, never one numberReal human RCT data, narrow indication, orphaned program
Bottom line
A genuinely de-risked EPO-derived peptide with multiple completed Phase 2 trials showing objective nerve-fiber regrowth in sarcoidosis and diabetic small-fiber neuropathy, but it never reached Phase 3, isn't FDA-approved, and the broad "nerve repair / anti-inflammatory" claims sold to the gray market far outrun the evidence.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported/trialed dosing centers on 4 mg subcutaneously once daily, the dose that showed the most consistent benefit in dose-ranging work (which compared 1 mg, 4 mg, and 8 mg).
Reported, not prescribed. Verify your vial and your math.
First documented human use
First documented human exposure dates to approximately 2009-2011. The earliest published controlled trial (Heij et al., Molecular Medicine, received Nov 2012) tested IV ARA 290 in 22 sarcoidosis patients and explicitly references pre-existing safety data from healthy volunteers and patients with kidney disease and diabetes, so first-in-human dosing preceded that publication. Unlike most gray-market peptides, ARA-290 HAS completed controlled human trials, the blank here is not "no human data" but "no Phase 3 and no regulatory approval."
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- An 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), engineered to keep EPO's tissue-protective and anti-inflammatory signaling while removing the red-blood-cell-stimulating (and clot-promoting) effect.
- Assumed to act as an agonist at the 'innate repair receptor' (IRR), a proposed heterodimer of the EPO receptor and the beta-common receptor (CD131) that is upregulated mainly in injured or inflamed tissue.
- Studied most seriously for small-fiber neuropathy (sarcoidosis and type 2 diabetes), where Phase 2 trials reported objective increases in corneal/skin nerve fiber density alongside reduced neuropathic pain.
- Marketed in the gray market for general nerve repair, chronic inflammation, autoimmune conditions, and long-COVID neuropathy, uses that go well beyond the trialed indications.
- Sold by Araim Pharmaceuticals' clinical program as cibinetide; that program did not complete Phase 3 and the compound remains investigational, not approved.
The data behind each bullet
What actually backs it
In sarcoidosis-associated small-fiber neuropathy, 28 days of ARA 290 increased corneal small-nerve-fiber density (objective confocal-microscopy endpoint) and reduced neuropathic pain versus placebo in a Phase 2 dose-ranging RCT (n=64; 4 mg arm).
Completed, registered, peer-reviewed Phase 2 RCT with an objective structural endpoint (corneal confocal microscopy), not just self-reported pain. NCT02039687 / Culver et al., IOVS 2017.
ClinicalTrials.gov NCT02039687 (Phase 2, sarcoidosis SFN) ↗In type 2 diabetes patients with neuropathic pain, 28 days of 4 mg SC ARA 290 improved PainDetect scores and modestly improved HbA1c and lipid ratios versus placebo (n=48).
Double-blind placebo-controlled Phase 2 trial (Brines et al., Mol Med 2015). Objective metabolic endpoints support it, but sample is small and single-sponsor.
PubMed: ARA 290 type 2 diabetes metabolic/neuropathic trial ↗The earliest controlled sarcoidosis trial (IV ARA 290, n=22) reported good tolerability and improved patient-reported symptoms, establishing early-phase human proof of concept.
Small single-site pilot (Heij et al., Mol Med 2012); pilot-scale, used as the launch point for later better-powered RCTs.
PubMed: Heij ARA 290 sarcoidosis pilot ↗Broader claims (general nerve regeneration, chronic inflammation, autoimmune disease, long-COVID neuropathy, performance/recovery) rest on animal and in-vitro work, not completed human trials.
Preclinical only: rodent neuritis/neuropathic-pain models, experimental colitis in mice, islet-allograft models. No published human RCT for these indications.
PubMed: cibinetide ARA-290 preclinical/animal studies ↗No Phase 3 trial was completed and ARA-290/cibinetide is not FDA-approved for any indication.
No marketing authorization exists; the clinical program stalled at Phase 2 and the sponsor wound down. Absence of approval is itself well-documented.
DailyMed (no approved cibinetide / ARA-290 label) ↗Mechanism
How it's assumed to work
Assumed mechanism: ARA-290 is modeled on the helix-B surface of erythropoietin and is thought to act as a selective agonist at the "innate repair receptor" (IRR), a proposed heterodimer of the EPO receptor (EPOR) and the beta-common receptor (CD131/βcR). This receptor is reported to be upregulated specifically in injured or inflamed tissue and largely absent in healthy cells, which is the proposed basis for a targeted, low-side-effect repair signal. Binding is theorized to trigger anti-apoptotic, anti-inflammatory (cytokine-dampening) and pro-regenerative signaling, with downstream effects on nociception (some work implicates TRPV1). The IRR's exact composition and even its existence as a discrete receptor remain debated in the literature, so this should be read as the assumed/working mechanism, not settled fact, even though ARA-290 itself has real human trial data.
Dosing & handling
What users and clinicians report
Reported/trialed dosing centers on 4 mg subcutaneously once daily, the dose that showed the most consistent benefit in dose-ranging work (which compared 1 mg, 4 mg, and 8 mg). Trial courses ran ~28 days; the earliest pilot used 2 mg IV three times weekly for 4 weeks. Gray-market protocols typically copy the 4 mg/day SC pattern, often in cycles (e.g., several weeks on), but cycling and total duration are extrapolated by users, not established by any approval.
This is reported, not prescribed. ARA-290 is investigational and not FDA-approved; there is no sanctioned human dose, and all gray-market dosing copies a 28-day trial protocol while extending it indefinitely without supporting data. Doses in trials were prepared as sterile, quality-controlled material, research-peptide vials are not, so real-world identity, purity, and per-vial content are unverified. Anyone considering it should do so only under qualified medical supervision.
Timing & food
Trials used once-daily subcutaneous injection (commonly into the anterior thigh with rotating sites), not tied to meals, food/fasting state is not a documented variable because the effect is receptor-mediated tissue repair, not a metabolic or anabolic pulse. Given the very short half-life, time-of-day is largely a matter of routine/adherence rather than pharmacology; users typically pick a consistent daily time. There is no evidence that fasted vs fed administration changes outcomes.
Half-life
Very short in plasma: terminal half-life roughly 20 minutes after subcutaneous dosing (peak ~3 ng/mL after 4 mg SC), and only ~2 minutes after IV. The clinical effects (nerve regrowth, symptom relief over weeks) far outlast drug presence in blood, consistent with a receptor-triggered repair cascade rather than sustained circulating exposure, a key reason once-daily dosing was used despite the brief half-life.
Reconstitution sensitivity
As a peptide it is supplied lyophilized and is handling-sensitive. Store lyophilized powder refrigerated (2-8 C) and protected from light; reconstitute gently with bacteriostatic or sterile water (do not shake vigorously). Use reconstituted solution promptly, within ~24 hours if held at room temperature, and refrigerate reconstituted material, avoiding freeze-thaw cycles. Gray-market product also carries unverified starting purity and content, which compounds any handling degradation.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Low. Despite being one of the more legitimately studied peptides, organic community discussion is thin, searches surface mostly clinical literature plus vendor and practitioner-clinic marketing pages rather than large volumes of first-person user reports on forums. It is a niche compound used for a niche problem (neuropathy), so it lacks the broad biohacker chatter of BPC-157 or GLP-1 drugs.
Consistency
Mixed and hard to read. Where anecdote exists, people with genuine neuropathic pain sometimes report gradual reductions in burning/tingling and better autonomic symptoms over weeks; others report little or nothing, and effects are described as subtle and slow rather than dramatic. Because it is so often stacked with BPC-157/TB-500 and lifestyle changes, even positive reports are inconsistent and confounded.
Source credibility
Weak as anecdote, but the underlying science is unusually credible for this category. Much of the favorable online content is affiliate/vendor or clinic marketing and should be discounted. The trustworthy signal here comes from the published Phase 2 trials (objective corneal-nerve and metabolic endpoints), not from forum testimonials, which is the opposite of most gray-market peptides where only anecdote exists.
- Reported as a 'feel-nothing-then-gradually-better' compound for nerve pain, users with diabetic or idiopathic small-fiber neuropathy describe slow, subtle reductions in burning, tingling, or numbness over weeks rather than any acute effect (anecdote, not proof).
- Commonly run alongside BPC-157 and/or TB-500 for nerve and soft-tissue 'repair' stacks, which makes individual attribution to ARA-290 very murky (anecdote).
- Frequently praised for a clean tolerability profile, people note minimal side effects beyond occasional injection-site irritation, consistent with the trial data (anecdote).
- A meaningful share of users report little to no perceptible benefit, and some question whether gray-market product is the correct, pure peptide at all, disappointment and source-skepticism are recurring themes (anecdote).
Placebo risk, Moderate
Moderate rather than High specifically because the strongest trial endpoints were objective and measurable, corneal/skin nerve fiber density by confocal microscopy, plus HbA1c and lipid changes, which are hard to placebo. The reason it isn't Low: most real-world users are chasing subjective outcomes (pain, tingling, fatigue, general inflammation) that are highly placebo-susceptible, they dose without the controls of a trial, and the pain-questionnaire improvements in trials, while real, were modest in absolute terms.
Risk panel
What could go wrong
Adverse events
In trials, adverse events were mostly mild: transient injection-site reactions, occasional headache, mild GI discomfort. Crucially, no clinically significant hematologic changes (no rise in hemoglobin/hematocrit), the whole design intent, and no anti-drug antibodies detected. The type 2 diabetes trial recorded 4 serious adverse events with 2 deemed possibly related but with uncertain causality, in an older, comorbid diabetic population; this is the main asterisk on an otherwise clean short-term profile.
Theoretical concerns
Mechanistically reassuring on the classic EPO worry: because ARA-290 is engineered NOT to activate the homodimeric EPO receptor that drives red-cell production, it should not raise hematocrit, blood pressure, or thrombosis risk the way EPO does, and trials support that. Residual theoretical concerns: the IRR triggers anti-apoptotic and pro-survival/repair signaling, so the open (unproven in humans) question is whether chronic, long-term, unsupervised agonism could be unfavorable in the setting of occult malignancy or unwanted tissue proliferation. No human signal for this exists, but no long-term human data exists either.
Contraindications
Not an approved drug, so there are no formal contraindications, only prudent ones. Caution/avoidance is reasonable in active or recent cancer (pro-survival signaling, unproven relevance), pregnancy and breastfeeding (no data), and anyone unable to verify product identity/purity from a research-peptide vendor. Diabetics or those on glucose-lowering or lipid therapy should note the small metabolic effects seen in trials and monitor accordingly. Unlike erythropoietin itself, it is not expected to be contraindicated in uncontrolled hypertension, but that rests on mechanism plus short-term data, not long-term safety studies.
Honest unknowns
The big unknowns are duration and source. Human exposure in trials capped at roughly 28 days (some IV pilots ~4 weeks); there is no controlled data on months-to-years of self-administration as used in the gray market. Long-term safety, repeat-cycle safety, and effects outside the two trialed neuropathy populations are simply not established. On top of that, gray-market product carries the usual unknowns: actual peptide identity, purity, correct sequence, endotoxin, and accurate dosing, none of which the clinical safety record covers.
Confound watch
In the community, ARA-290 is very commonly stacked with BPC-157 and/or TB-500 for "nerve and tissue repair," and frequently layered onto an existing regimen of better glycemic control, anti-inflammatory diet changes, physical therapy, or other peptides. Sarcoidosis and diabetic neuropathy also wax and wane on their own. Any single-user "it worked" report is therefore heavily confounded, attribution to ARA-290 specifically is rarely clean, and there is no clinical data on the combination stacks people actually run.
History
Discovery → first use → status
- ~2008-2010Helix-B surface peptide / ARA 290 developed (Brines, Cerami and colleagues) to separate EPO's tissue-protective signaling from erythropoiesis; Araim Pharmaceuticals advances it as cibinetide. First-in-human dosing in this window.
- 2012First controlled human trial published: IV ARA 290 in 22 sarcoidosis patients with small-fiber neuropathy (Heij et al., Molecular Medicine), well tolerated, symptom improvement.
- 2013Phase 2 sarcoidosis RCT (Dahan et al., n=36) reports increased corneal nerve fiber density sustained at follow-up.
- 2014-2015Phase 2b dose-ranging sarcoidosis trial (NCT02039687, n=64) completed; Phase 2 type 2 diabetes neuropathy/metabolic trial (Brines et al., 2015) published.
- 2017Culver et al. (IOVS) report placebo-corrected increase in corneal nerve fiber area at the 4 mg dose, a key objective regeneration signal.
- 2020Phase 2 trial of cibinetide for diabetic macular edema published (J Clin Med); broader ophthalmic/metabolic exploration continues at small scale.
- 2020sClinical program does not advance to a completed Phase 3; no FDA approval. Compound migrates into the gray/research-peptide market and practitioner clinics for off-label nerve and inflammation use.
Verification
The COA standard, applied
Verified across registered clinical trials and peer-reviewed literature: ClinicalTrials.gov NCT02039687 (Araim Pharmaceuticals, Phase 2, sarcoidosis SFN, n=64, completed); Heij et al. (Mol Med 2012, sarcoidosis pilot); Brines et al. (Mol Med 2015, type 2 diabetes); Culver et al. (IOVS 2017, corneal nerve fiber). Pharmacokinetics (terminal half-life ~20 min SC) sourced from the published type 2 diabetes trial. No FDA approval found on DailyMed. All citations are real, resolvable PubMed-search / ClinicalTrials.gov / DailyMed URLs; no PMIDs, titles, or statistics were invented.
The full verification standard →Sources
Where this comes from
- ClinicalTrials.gov NCT02039687. Phase 2 sarcoidosis SFN dose-ranging (Araim, n=64, completed) ↗· Primary registered trial; confirms sponsor, phase, doses (1/4/8 mg SC), enrollment, completion 2015.
- PubMed, cibinetide / ARA-290 (all results) ↗· Master list separating human Phase 2 trials (sarcoidosis, T2D, diabetic macular edema) from animal/in-vitro work.
- PubMed. Heij ARA 290 sarcoidosis small-fiber-neuropathy pilot (Mol Med 2012) ↗· Earliest controlled human trial; anchors first-documented-human-use timeline (~2010-2012).
- PubMed. ARA 290 type 2 diabetes neuropathy & metabolic trial (Brines, Mol Med 2015) ↗· Phase 2 RCT; source of PK (t1/2 ~20 min SC), PainDetect, HbA1c/lipid, and the 4 SAEs/no-ADA safety detail.
- PubMed, cibinetide / ARA-290 preclinical (animal/in-vitro) ↗· Supports that broader anti-inflammatory/autoimmune/repair claims are animal-stage only (Grade D).
- DailyMed, cibinetide search (no approved label) ↗· Confirms no FDA-approved product; compound remains investigational.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.